Allogene Therapeutics Inc

ALLO · NASDAQ

Research and Development in Biotechnology

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

ESG Overview

Overall: BBB (High)

E: AS: BBG: BB

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $2.66 +0.16 (+6.40%)

Market Cap$562M

P/E Ratio—

EPS$—

52W High$2.80

52W Low$0.86

Beta0.55

Data from Finnhub · Updated Mar 10, 2026